Study Finds RSV Vaccine Elicits Robust Immune Responses Among Younger Adult Populations

Infectious Disease Advisor (2/19, Nye) reports that in a study, “a respiratory syncytial virus (RSV) vaccine was found to elicit robust immune responses among younger adult populations, including in those at increased risk for severe disease due to chronic cardiac or pulmonary comorbidities.” The researchers said, “Prevention of RSV through vaccination could have a substantial impact on the disease burden due to RSV, particularly in those at increased risk.” The findings were published in Vaccine.